I-Entecavir CAS 142217-69-4 API Factory High Quality Anti-HBV
Ukunikezela Komkhiqizi Ngokuhlanzeka Okuphezulu kanye Nekhwalithi Ezinzile
Igama Lekhemikhali: I-Entecavir
I-CAS: 142217-69-4
I-antiviral esetshenziswa ekwelapheni i-Hepatitis B Infection
Ikhwalithi ephezulu ye-API, Ukukhiqiza Kwezentengiso
Igama Lekhemikhali | I-Entecavir |
Omqondofana | 2-Amino-1,9-dihydro-9-[(1S,3R,4S)-4-hydroxy-3-(hydroxymethyl)-2-methylenecyclopenyl]-6H-purin-6-one |
Inombolo ye-CAS | 142217-69-4 |
Inombolo yeCAT | I-RF-API80 |
Isimo Sesitoko | Esitokweni, Isikali Sokukhiqiza Sifika Emakhulwini Amakhilogremu |
I-Molecular Formula | I-C12H15N5O3 |
Isisindo samangqamuzana | 277.28 |
I-Melting Point | 249.0~252.0℃ |
Ibhrendi | I-Ruifu Chemical |
Into | Imininingwane |
Ukubukeka | I-Crystalline Powder Emhlophe |
Ukuhlonza IR | I-spectrum yokumuncwa kwe-infraed yesampula yokuhlola kufanele ihambisane nezinga lereferensi |
Ukuhlonza HPLC | Isikhathi sokugcinwa kwesampula yokuhlola sihambisana naleso sezinga lesithenjwa |
pH | 5.5~7.5 |
I-Specific Optical Rotation | +24.0°-+28.0° (DMF: MeOH=1:1 C=1%) |
Izinto Ezihlobene | |
Ukungcola Okuphelele | ≤0.30% |
Ukungcola Okukodwa Okukhulu | ≤0.10% |
I-Enantiomer | ≤0.20% |
Izincibilikisi Ezisele | |
I-Methanol | ≤0.30% |
I-Dichloromethane | ≤0.06% |
n-Hexane | ≤0.029% |
I-Tetrahydrofuran | ≤0.072% |
I-N, N-Dimethylformamide | ≤0.088% |
I-Toluene | ≤0.089% |
Okuqukethwe Amanzi | 5.8%~6.5% |
Izinsalela ekushiseni | ≤0.10% |
Izinsimbi Ezisindayo | ≤20ppm |
Isivivinyo | 98.0%~102.0% (C12H15N5O3 ibalwa ngesisekelo se-anhydrous) |
Usayizi Wezinhlayiyana | I-D90: ≤100µm |
Izinga Lokuhlola | I-Enterprise Standard |
Ukusetshenziswa | I-API, isidakamizwa esilwa namagciwane esisetshenziswa ekwelapheni i-Hepatitis B Infection |
Iphakheji: Ibhodlela, isikhwama se-Aluminium foil, isigubhu seCardboard, 25kg/Drum, noma ngokwezidingo zekhasimende.
Isimo Sesitoreji:Gcina ezitsheni ezivaliwe endaweni epholile neyomile;Vikela ekukhanyeni, umswakama kanye nezinambuzane.
I-Entecavir isizukulwane esisha se-guanine nucleoside analogues imithi yomlomo yokwelashwa kwe-Hepatitis B Virus (HBV) ukutheleleka, ikakhulukazi ekwelapheni iziguli ezikhulile ezinomsebenzi wokuphindaphinda kwegciwane kanye ne-serum transaminase yaqhubeka nokukhula, noma izicubu zesibindi zomsebenzi we-pathological we-hepatitis B engapheli. , okwamanje igciwane eliphansi lishesha kakhulu futhi linamandla kakhulu, izinga lokuguqulwa kwama-nucleoside analogue eliphansi kakhulu.Idatha ibonisa ukuthi okuhlukile ezigulini ezine-hepatitis B engapheli, kuhlanganise ne-nucleoside naive kanye ne-nucleoside ephathwayo kanye neziguli ze-cirrhosis yesibindi, ukusebenzisa amaphilisi e-entecavir kahle ekwelapheni kungalawula lesi sifo ngokushesha futhi kufinyelele kalula ukwelashwa kokuphela kweqiniso, okuyigciwane le-hepatitis B elingenakulinganiswa;ngokubambelela ekwelashweni, ingxenye enkulu yeziguli ingafika ekupheleni kokwaneliseka kokwelashwa, okungukuthi ukuguqulwa kwe-antigen serology, ezinye iziguli zingakwazi ngisho nokufinyelela ekahle yokwelashwa kokuphela, okungukuthi i-surface antigen negative.